Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bert Oosthuyse is active.

Publication


Featured researches published by Bert Oosthuyse.


Cell | 1999

Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis

Peter Carmeliet; MariaGrazia Lampugnani; Lieve Moons; Ferrucio Breviario; Veerle Compernolle; Françoise Bono; Giovanna Balconi; Raffaella Spagnuolo; Bert Oosthuyse; Mieke Dewerchin; Adriana Zanetti; Anne Angellilo; Virginie Mattot; Dieter Nuyens; Esther Lutgens; Frederic Clotman; Marco C. de Ruiter; Adriana C. Gittenberger-de Groot; Robert E. Poelmann; Florea Lupu; Jean-Marc Herbert; Desire Collen; Elizabetta Dejana

Vascular endothelial cadherin, VE-cadherin, mediates adhesion between endothelial cells and may affect vascular morphogenesis via intracellular signaling, but the nature of these signals remains unknown. Here, targeted inactivation (VEC-/-) or truncation of the beta-catenin-binding cytosolic domain (VECdeltaC/deltaC) of the VE-cadherin gene was found not to affect assembly of endothelial cells in vascular plexi, but to impair their subsequent remodeling and maturation, causing lethality at 9.5 days of gestation. Deficiency or truncation of VE-cadherin induced endothelial apoptosis and abolished transmission of the endothelial survival signal by VEGF-A to Akt kinase and Bcl2 via reduced complex formation with VEGF receptor-2, beta-catenin, and phosphoinositide 3 (PI3)-kinase. Thus, VE-cadherin/ beta-catenin signaling controls endothelial survival.


Nature Genetics | 2001

Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration

Bert Oosthuyse; Lieve Moons; Erik Storkebaum; Heike Beck; Dieter Nuyens; Koen Brusselmans; Jo Van Dorpe; Peter Hellings; Marchel Gorselink; Stephane Heymans; Gregor Theilmeier; Mieke Dewerchin; Vincent Laudenbach; Patrick Vermylen; Harold Raat; Till Acker; Vicky Vleminckx; Ludo Van Den Bosch; Neil R. Cashman; Hajime Fujisawa; Maarten R. Drost; Raf Sciot; Frans Bruyninckx; Daniel J. Hicklin; Can Ince; Pierre Gressens; Florea Lupu; Karl H. Plate; Wim Robberecht; Jean-Marc Herbert

Hypoxia stimulates angiogenesis through the binding of hypoxia-inducible factors to the hypoxia-response element in the vascular endothelial growth factor (Vegf) promotor. Here, we report that deletion of the hypoxia-response element in the Vegf promotor reduced hypoxic Vegf expression in the spinal cord and caused adult-onset progressive motor neuron degeneration, reminiscent of amyotrophic lateral sclerosis. The neurodegeneration seemed to be due to reduced neural vascular perfusion. In addition, Vegf165 promoted survival of motor neurons during hypoxia through binding to Vegf receptor 2 and neuropilin 1. Acute ischemia is known to cause nonselective neuronal death. Our results indicate that chronic vascular insufficiency and, possibly, insufficient Vegf-dependent neuroprotection lead to the select degeneration of motor neurons.


Archive | 2001

Use of VEGF and homologues to treat neuron disorders

Peter Carmeliet; Desire Collen; Bert Oosthuyse


Archive | 2002

Deletion of the hypoxia-response element in the VEGF promoter causes adult onset motor neuron degeneration

Diether Lambrechts; Erik Storkebaum; Lieve Moons; Bert Oosthuyse; Mieke Dewerchin; J. Van Dorpe; Neil R. Cashman; Bart De Strooper; Raphael Sciot; Wim Robberecht; Karl H. Plate; Jean-Marc Herbert; Desire Collen; Peter Carmeliet


Archive | 2001

USE OF VEGF 165 AND HOMOLOGUES TO TREAT NEURON DISORDERS

Peter Carmeliet; Desire Collen; Bert Oosthuyse


Archive | 2001

The use of vegf165 to treat neuron disorders

Peter Carmeliet; Desire Collen; Bert Oosthuyse


Archive | 2001

Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen

Peter Carmeliet; Desire Collen; Bert Oosthuyse


Archive | 2001

Use of VEGF and homologs for treating neurological disorders

Peter Carmeliet; Desire Collen; Bert Oosthuyse


Archive | 2001

Use of VEGF and homologs for treatment of neuronal diseases

Peter Carmeliet; Desire Collen; Bert Oosthuyse


Archive | 2001

Use of VEGF 165 and homologs for treating neuronal diseases

Peter Carmeliet; Desire Collen; Bert Oosthuyse

Collaboration


Dive into the Bert Oosthuyse's collaboration.

Top Co-Authors

Avatar

Peter Carmeliet

Katholieke Universiteit Leuven

View shared research outputs
Top Co-Authors

Avatar

Desire Collen

Hebrew University of Jerusalem

View shared research outputs
Top Co-Authors

Avatar

Desire Collen

Hebrew University of Jerusalem

View shared research outputs
Top Co-Authors

Avatar

Mieke Dewerchin

Katholieke Universiteit Leuven

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dieter Nuyens

Katholieke Universiteit Leuven

View shared research outputs
Top Co-Authors

Avatar

Lieve Moons

Katholieke Universiteit Leuven

View shared research outputs
Top Co-Authors

Avatar

Wim Robberecht

Katholieke Universiteit Leuven

View shared research outputs
Top Co-Authors

Avatar

Florea Lupu

Oklahoma Medical Research Foundation

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge